title: Use of the flare-up protocol with high dose human follicle stimulating hormone and human menopausal gonadotropins for in vitro fertilization in poor responders.
abstract: OBJECTIVE
  To analyze the effect of high dose human FSH in combination with hMG with a flare-up leuprolide acetate (LA) protocol in patients undergoing IVF at risk for a poor response.
  
  
  METHODS
  Prospective.
  
  
  METHODS
  Free-standing ambulatory IVF center.
  
  
  METHODS
  Two hundred eighty-four patients underwent a LA screening test for IVF. Patients with a lack of flare response were considered at risk for a poor response and underwent ovarian stimulation with the flare-up LA protocol in combination with high dose human FSH and hMG.
  
  
  RESULTS
  The poor responder group was compared with the good responders on the flare-up LA protocol and to patients undergoing ovulation induction with a luteal phase LA protocol. There were 53 poor responder flare-up LA cycles, 177 good responder flare-up LA cycles, and 54 luteal phase LA cycles. The cancellation rate was higher in poor flare-up LA responders (11.3 percent) compared with good flare-up LA responders (1.1 percent) and luteal phase LA cycles (1.8 percent). Peak E2 levels, number of oocytes, and number of embryos were significantly higher in the good flare-up LA responders. Fertilization rate was similar in all groups. Ongoing pregnancy rate per retrieval was 28 percent in good responders, 29 percent in poor responders, and 33 percent in luteal phase LA patients. Only one patient (0.4 percent) was hospitalized for severe ovarian hyperstimulation.
  
  
  CONCLUSIONS
  The flare-up protocol with high-dose human FSH and hMG is a very good alternative for patients who are at high risk for a poor response. Although peak E2 and number of oocytes were significantly lower in this group, the patients who responded had the same fertilization and pregnancy rate as the good responders. Cancellation rate remains high in poor responders.
authors.affiliation: Fertility Center of Maryland, Baltimore, USA.
authors.forename: S L
authors.initials: SL
authors.lastname: Padilla
authors.forename: K
authors.initials: K
authors.lastname: Dugan
authors.forename: V
authors.initials: V
authors.lastname: Maruschak
authors.forename: S
authors.initials: S
authors.lastname: Shalika
authors.forename: R D
authors.initials: RD
authors.lastname: Smith
mesh_terms: D000328:Adult; D002985:Clinical Protocols; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage* / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D007247:Infertility, Female / Q000097:blood / Q000188:drug therapy* / Q000628:therapy*; D016729:Leuprolide / Q000008:administration & dosage; D008297:Male; D008596:Menotropins / Q000008:administration & dosage*; D011247:Pregnancy; D011446:Prospective Studies
chemical_list: D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D008596:Menotropins; D005640:Follicle Stimulating Hormone; D016729:Leuprolide